IR News

IR Information

ALL Financial Statements Timely Disclosure IR Others

2025.05.16Timely Disclosure
Frequently Asked Questions and Answers(1MB)
2025.05.14Financial Statements
Non-consolidated Financial Results for the Year Ended March 31, 2025 [Japanese GAAP](268KB)
2025.05.13Timely Disclosure
Announcement of winning the TOP40 (semi-finalists) and receiving the prize money in the global longevity competition XPRIZE Healthspan(300KB)
2025.05.07Timely Disclosure
Notice of additional grant confirmation for Innovative Cancer Medical Practical Research Project by the Japan Agency for Medical Research(124KB)
2025.04.09Timely Disclosure
Notification of achievement of target number of registered cases in clinical performance test for regulatory approval of programmed medical devic(114KB)
2025.03.06Timely Disclosure
Achievement of primary endpoint of confirmatory clinical performance trial of the artificial intelligence (AI) to predict insulin dosage(226KB)
2025.02.18Timely Disclosure
Announcement of initiation (patient administration begins) of the Phase III trial of malignant melanoma treatment drug RS5614(166KB)
2025.02.12Timely Disclosure
Notice of receipt of lump sum payment due to the exercise of option right by Chest Co., Ltd. for the artificial intelligence (AI)-based medical software to diagnose respiratory diseases by the spirometry(112KB)
2025.01.27Timely Disclosure
Frequently Asked Questions and Answers(137KB)
2025.01.22Timely Disclosure
Opening of the laboratory of the Potocsnak Longevity Institute of Northwestern University at the Tohoku University Renascience Open Innovation Lab (TREx)(265KB)
2025.01.16Timely Disclosure
Prompt announcement of the result of the clinical performance test for the artificial intelligence(113KB)
2025.01.09Timely Disclosure
Announcement of the results of the Phase I clinical trial with ET-02 (Active Ingredient RS5441) for the for the treatment of androgenetic alopecia (AGA) and age-related hair loss at Eirion Therapeutics, Inc., USA(131KB)
2025.01.06Timely Disclosure
Announcement of approval by the Institutional Review Board of Tohoku University for Phase III trial of drug for the treatment of malignant melanoma(178KB)
2024.12.26Timely Disclosure
Announcement of completion to enroll the planned sample size in the investigator-initiated Phase II clinical trial with a PAI-1 inhibitor RS5614 in systemic sclerosis (scleroderma)-associated interstitial lung disease (SSc-ILD)(156KB)
2024.12.06Timely Disclosure
Notice of Revision of Full-Year Earnings Forecasts for the Fiscal Year Ending March , 2025(156KB)
2024.12.03Timely Disclosure
Notice of 2-year extension of the grant period for the Innovative Cancer Medical Practical Research Project by the Japan Agency for Medical Research and Development (AMED)(131KB)
2024.11.25Timely Disclosure
Notice of termination of joint development and option contract with ASKA Pharmaceutical Co., Ltd. regarding PMSPMDD treatment drug(101KB)
2024.11.05Timely Disclosure
Notice of the completion of a joint development agreement with Taipei Medical University (TMU)-Biotech Co., Ltd. (Taipei) for the PAI-1 inhibitor RS5614.(87KB)
2024.10.21Timely Disclosure
Notice of start of clinical performance testing of artificial intelligence (AI) to predict total water removal volume in maintenance hemodialysis patien(137KB)
2024.09.12Timely Disclosure
Notice of Acquisition and Cancellation of Stock Acquisition Rights (Stock Options)(205KB)
2024.09.10Timely Disclosure
Announcement of notification of selection for the Japan Agency for Medical Research and Development (AMED) Smart Bio Drug Discovery Research Support Program(113KB)
2024.09.02Timely Disclosure
Announcement of Initiation of PAI-1 inhibitor RS5614 for malignant melanoma designated as Orphan Drug(150KB)
2024.08.30Timely Disclosure
Announcement of the joint R&D collaboration agreement for artificial intelligence (AI)-based software as a medical device (SaMD) with Taipei Medical University (TMU)-Biotech Co., Ltd.(86KB)
2024.08.19Timely Disclosure
Announcement of Initiation of clinical performance trial of artificial intelligence (AI) to predict insulin dosage for diabetes patients(118KB)
2024.07.03Timely Disclosure
Notice of Revision of Full-Year Earnings Forecasts for the Fiscal Year Ending March , 2025(154KB)
2024.07.03Timely Disclosure
Announcement of Initiation of Phase I Study by Eirion Therapeutics, Inc. in the U.S.(121KB)
2024.06.24Timely Disclosure
Notice of Conclusion of Collaboration Agreement with Luxna Biotech Co., Ltd.(94KB)
2024.06.24Timely Disclosure
Announcement of Initiation of Multicenter Clinical Study on Disposable Ultrafine Endoscopes(123KB)
2024.06.21Timely Disclosure
Results of Phase II Investigator-Initiated Clinical Trial of Pyridoxamine RS8001 for Premenstrual Syndrome with Psychiatric Symptoms /Premenstrual Dysphoric Disorder(273KB)
2024.06.07Others
Notice of Publication of Results from Phase II Trial of the PAI-1 Inhibitor in Advanced Malignant Melanoma(115KB)
2024.05.27Timely Disclosure
Notice of Change of Representative Director and Directors(143KB)
2024.05.27Timely Disclosure
Notice of Partial Amendment to Articles of Incorporation(146KB)
2024.05.20Timely Disclosure
Notice of Conclusion of License Agreement with HI-LEX Medical for Disposable Ultrafine Endoscope(225KB)
2024.05.20Timely Disclosure
Notice of Termination of License Agreement with Baxter Healthcare Corporation for Disposable Ultrafine Endoscope(190KB)
2024.05.09Timely Disclosure
Notice of Change in Use of Fund Raised at the Listing, and Scheduled Time and Amount of Expenditure(211KB)
2024.05.09Timely Disclosure
Notice of Difference between Financial Forecast and Actual Results(119KB)
2024.05.09Timely Disclosure
Notice of Extraordinary Loss (Impairment Loss)(110KB)
2024.03.18Others
Notice of Publication of Article Related to the C o mpany s Software as a Medical Device in Nature(106KB)
2024.03.14Timely Disclosure
Notice of Conclusion of Collaboration Agreement with Nipro Corporation(143KB)
2024.03.07Timely Disclosure
Participation in the Program on Open Innovation Platform with Enterprises, Research Institute and Academia (OPERA) of Japan Science and Technology Agency (JST)(296KB)
2024.02.22Timely Disclosure
Final Results of Phase II Investigator-Initiated Clinical Trial of PAI-1 inhibitor RS5614 for Malignant Melanoma Refractory to Nivolumab(227KB)
2024.02.06Timely Disclosure
Completion of Treatment of Final Patient in Phase II Investigator-Initiated Clinical Trial of RS8001 (pyridoxamine) for Premenstrual Syndrome with Psychiatric Symptoms/Premenstrual Dysphoric Disorder(130KB)
2023.12.08Timely Disclosure
Notice of Conclusion of Collaboration Agreement with Toray Medical Co., Ltd(144KB)
2023.12.05Timely Disclosure
Notice of Allowance of New Use and Dosage Patent for PAI-1 Inhibitor(Title of the Invention: Inhibitor against Expression of Immune Checkpoint Molecule)(124KB)
2023.10.26Timely Disclosure
Announcement of Initiation of Phase II Study for Cutaneous Angiosarcoma(144KB)
2023.10.19Timely Disclosure
Announcement of Initiation of Phase II study for the treatment of interstitial lung disease associated with systemic scleroderma begins.(308KB)
2023.10.17Timely Disclosure
Notice of Allowance of New Use and Dosage Patent for PAI-1 Inhibitor (Title of the Invention: Drug for Enhancing Fibrinolytic System, and Use Thereof)(135KB)
2023.09.26Timely Disclosure
Announcement of Initiation of Phase II Study for Non-Small Cell Lung Cancer.(184KB)
2023.09.07Others
Notice of Publication of A rticle on PAI 1 I nhibitor in Nature(132KB)
2023.09.06Timely Disclosure
Achievement of Enrollment Goal in Phase II Investigator-Initiated Clinical Trial of RS8001 (pyridoxamine) for the Treatment of Patients with Psychiatric Symptoms of Premenstrual Syndrome/Premenstrual Dysphoric Disorder(143KB)
2023.08.16Timely Disclosure
PAI-1 Inhibitor RS5614 Met Primary Endpoint in Phase II Investigator-Initiated Clinical Trial for Malignant Melanoma Refractory to Nivolmab(232KB)
2023.06.28Timely Disclosure
Notice of Change in Major Shareholder(185KB)
2023.06.23Timely Disclosure
Results of Phase II Investigator-Initiated Clinical Trial to Evaluate the Safety and Efficacy of RS5614 in Combination with Nivolumab for the Treatment of Malignant Melanoma(290KB)
2023.06.19Timely Disclosure
Notice of Exercise of Option under License Agreement with Eirion Therapeutics, Inc.(151KB)
2023.06.14Timely Disclosure
Notice of Receipt of Milestone Under License Agreement with Chest MI Inc on AI for Respiratory Function Diagnosis(185KB)
2023.06.12Timely Disclosure
Announcement of Conclusion of Collaboration Agreement with NEC Corporation (NEC)(178KB)
2023.06.05Timely Disclosure
Notice of Conclusion of Collaboration Agreement with Kyoto University and Daiichi Sankyo Company, Limited(299KB)
2023.04.24Timely Disclosure
Announcement of Agreement on Comprehensive Research Cooperation with Hiroshima University(233KB)
2023.04.17Timely Disclosure
Results of Placebo-Controlled, Double-Blind, Phase II Investigator-Initiated Clinical Trial of RS5614, a PAI-1 Inhibitor, for Novel Coronavirus (SARS-CoV-2) Pneumonia.(494KB)
2023.04.03Timely Disclosure
Notice of Receipt of Consideration for Exercise of Option for Exclusive Development and Commercialization Rights to Eirion Therapeutics, Inc.(186KB)
2023.03.15Timely Disclosure
Notice of Adoption in AMED Practical Research Program for Intractable Diseases in FY2023(235KB)
2023.03.09Timely Disclosure
Notice of Revision of Full-Year Earnings Forecasts for the Fiscal Year Ending March 31, 2023(182KB)
2023.02.27Timely Disclosure
Notice of Adoption of AMED Research on Development of New Medical Devices(113KB)
2022.12.26Timely Disclosure
Notification of Regulatory Approval of Disposable Ultrafine Endoscope(100KB)
2022.12.23Timely Disclosure
Announcement of Collaboration Agreement with Kyoto University(253KB)
2022.12.08IR
Key Questions and Answers at the Q2 FY2023 Financial Result Briefing(71KB)
2022.12.06IR
Financial Results Second Quarter of Fiscal Year Ending March 31, 2023(1MB)
2022.11.30Timely Disclosure
Announcement of Conclusion of Memorandom of Understanding with NEC Solution Innovators, Ltd.(189KB)
2022.11.28Timely Disclosure
Notice of Conclusion of Memorandum of Understanding with Daiichi Sankyo Company, Limited to Amend Agreement Concerning Preferential Negotiation Rights with Option Rights(147KB)
2022.10.31Timely Disclosure
Announcement of Collaboration Agreement with Hiroshima University(166KB)
2022.09.14Timely Disclosure
Notification of the Filing of a New Medical Device Registration for a Disposable Ultrafine Endoscope(94KB)
2022.09.01Timely Disclosure
Announcement of the Execution of the Collaboration Agreement with HI-LEX Corporation and its subsidiary HI-LEX Medical(173KB)
2022.08.03Timely Disclosure
Announcement of Initiation of Phase III Trials for Chronic Myeloid Leukemia(139KB)
2022.07.14Timely Disclosure
Notice of Acquisition and Cancellation of Stock Acquisition Rights (Stock Options)(189KB)
2022.06.29IR
Notice of Resolutions of the 23rd Ordinary General Meeting of Shareholders(335KB)
2022.06.22Timely Disclosure
(Change in Disclosure Item) Partial Change to Notice Concerning Transition to a Company with an Audit & Supervisory Committee and Changes in Directors and Corporate Auditors(98KB)
2022.06.09Timely Disclosure
Notice of Conclusion of Memorandum of Understanding with Daiichi Sankyo Company, Limited to Amend Agreement Concerning Preferential Negotiation Rights with Option Rights(95KB)
2022.05.30Timely Disclosure
Notice of Transition to a Company with an Audit Committee and Changes in Directors(119KB)
2022.05.30Timely Disclosure
Notice of Partial Amendments to the Articles of Incorporation(242KB)
2022.05.26Timely Disclosure
Notice of Conclusion of Memorandum of Understanding with Nipro Corporation to Change Joint Research Agreement(170KB)
2022.05.12Timely Disclosure
Notice Regarding the Recording of Extraordinary Losses（Impairment Losses）(151KB)
2022.05.12Financial Statements
Financial Results for the Fiscal Year Ended March 31, 2022 [Japanese GAAP] (Non-consolidated)(402KB)
2022.04.20Timely Disclosure
Noticre of Adoption of “Innovation in Medical Engineering (Development and Commercialization Project)” for FY2022(169KB)
2022.03.22Timely Disclosure
Announcement of the Adoption of the Project under AMED Research Program of “Practical Application of Innovative Cancer Therapy” in FY2022(169KB)
2022.03.17Timely Disclosure
Announcement of the Collaboration Agreement with Tokyo Medical and Dental University Hospital(177KB)
2022.02.14Timely Disclosure
Notice of Revision of Full-Year Earnings Forecasts for the Fiscal Year Ending March, 2022(137KB)
2022.02.14Timely Disclosure
Notice Concerning Recording of Non-Operating Expenses(160KB)
There are no items to be posted at this time.

Adobe Reader is required for viewing PDF files.
The Adobe Reader application can be downloaded for free from Adobe Systems.